Evolution and Innovations in Bone Marrow Cellular Therapy for Musculoskeletal Disorders: Tracing the Historical Trajectory and Contemporary Advances.

bone marrow mesenchymal stem cells orthopedics regenerative medicine

Journal

Bioengineering (Basel, Switzerland)
ISSN: 2306-5354
Titre abrégé: Bioengineering (Basel)
Pays: Switzerland
ID NLM: 101676056

Informations de publication

Date de publication:
28 Sep 2024
Historique:
received: 12 08 2024
revised: 23 09 2024
accepted: 25 09 2024
medline: 25 10 2024
pubmed: 25 10 2024
entrez: 25 10 2024
Statut: epublish

Résumé

Bone marrow cellular therapy has undergone a remarkable evolution, significantly impacting the treatment of musculoskeletal disorders. This review traces the historical trajectory from early mythological references to contemporary scientific advancements. The groundbreaking work of Friedenstein in 1968, identifying fibroblast colony-forming cells in bone marrow, laid the foundation for future studies. Caplan's subsequent identification of mesenchymal stem cells (MSCs) in 1991 highlighted their differentiation potential and immunomodulatory properties, establishing them as key players in regenerative medicine. Contemporary research has focused on refining techniques for isolating and applying bone marrow-derived MSCs. These cells have shown promise in treating conditions like osteonecrosis, osteoarthritis, and tendon injuries thanks to their ability to promote tissue repair, modulate immune responses, and enhance angiogenesis. Clinical studies have demonstrated significant improvements in pain relief, functional recovery, and tissue regeneration. Innovations such as the ACH classification system and advancements in bone marrow aspiration methods have standardized practices, improving the consistency and efficacy of these therapies. Recent clinical trials have validated the therapeutic potential of bone marrow-derived products, highlighting their advantages in both surgical and non-surgical applications. Studies have shown that MSCs can reduce inflammation, support bone healing, and enhance cartilage repair. However, challenges remain, including the need for rigorous characterization of cell populations and standardized reporting in clinical trials. Addressing these issues is crucial for advancing the field and ensuring the reliable application of these therapies. Looking ahead, future research should focus on integrating bone marrow-derived products with other regenerative techniques and exploring non-surgical interventions. The continued innovation and refinement of these therapies hold promise for revolutionizing the treatment of musculoskeletal disorders, offering improved patient outcomes, and advancing the boundaries of medical science.

Identifiants

pubmed: 39451354
pii: bioengineering11100979
doi: 10.3390/bioengineering11100979
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Auteurs

José Fábio Lana (JF)

Department of Orthopaedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.
Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
Medical School, Max Planck University Center (UniMAX), Indaiatuba 13343-060, SP, Brazil.
Clinical Research, Anna Vitória Lana Institute (IAVL), Indaiatuba 13334-170, SP, Brazil.
Medical School, Jaguariúna University Center (UniFAJ), Jaguariúna 13820-000, SP, Brazil.

Gabriela Caponero de Brito (GC)

Department of Orthopaedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.

André Kruel (A)

Department of Orthopaedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.

Benjamim Brito (B)

Department of Orthopaedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.

Gabriel Silva Santos (GS)

Department of Orthopaedics, Brazilian Institute of Regenerative Medicine (BIRM), Indaiatuba 13334-170, SP, Brazil.

Carolina Caliari (C)

Cell Therapy, In Situ Terapia Celular, Ribeirão Preto 14056-680, SP, Brazil.

Francesca Salamanna (F)

Surgical Sciences and Technologies, IRCCS Instituto Ortopedizo Rizzoli, 40136 Bologna, Italy.

Maria Sartori (M)

Surgical Sciences and Technologies, IRCCS Instituto Ortopedizo Rizzoli, 40136 Bologna, Italy.

Giovanni Barbanti Brodano (G)

Spine Surgery Unit, IRCCS Instituto Ortopedizo Rizzoli, 40136 Bologna, Italy.

Fábio Ramos Costa (FR)

Department of Orthopaedics, FC Sports Traumatology, Salvador 40296-210, BA, Brazil.

Madhan Jeyaraman (M)

Department of Orthopaedics, ACS Medical College and Hospital, Dr. MGR Educational and Research Institute, Chennai 600077, Tamil Nadu, India.
Orthopaedic Research Group, Coimbatore 641045, Tamil Nadu, India.
Clinical Research Scientist, Virginia Tech India, Chennai 600095, Tamil Nadu, India.

Ignácio Dallo (I)

Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
Medical School, Max Planck University Center (UniMAX), Indaiatuba 13343-060, SP, Brazil.
Orthopedics, SportMe Medical Center, 41013 Seville, Spain.

Pedro Bernaldez (P)

Orthopedics, SportMe Medical Center, 41013 Seville, Spain.

Joseph Purita (J)

Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
Medical School, Max Planck University Center (UniMAX), Indaiatuba 13343-060, SP, Brazil.

Marco Antonio Percope de Andrade (MAP)

Department of the Locomotor Apparatus, Federal University of Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.

Peter Albert Everts (PA)

Regenerative Medicine, Orthoregen International Course, Indaiatuba 13334-170, SP, Brazil.
Medical School, Max Planck University Center (UniMAX), Indaiatuba 13343-060, SP, Brazil.
Gulf Coast Biologics, Fort Myers, FL 33916, USA.

Classifications MeSH